Antiviral Peptides and SARS-CoV-2: Pandemic Lessons
Coronavirus Fusion Inhibitor Peptides
1.3 nM IC50
EK1C4, a lipopeptide fusion inhibitor, blocked SARS-CoV-2 spike-mediated membrane fusion at 1.3 nanomolar and protected mice from infection via intranasal delivery.
Xia et al., Cell Research, 2020
Xia et al., Cell Research, 2020
View as imageSARS-CoV-2 triggered the largest mobilization of antiviral peptide research in history. Within months of the virus's genetic sequence becoming available in January 2020, laboratories worldwide had identified peptides targeting its spike protein, main protease, host receptor, and entry machinery. Some reached single-digit nanomolar potency in cell culture. One, thymosin alpha-1, reduced mortality in a clinical cohort from 30% to 11%.[1] Yet as of early 2026, no antiviral peptide has been approved for COVID-19 treatment. The gap between laboratory performance and clinical deployment reveals both the promise and the structural limitations of peptide-based antivirals. This article examines what each major peptide strategy accomplished against SARS-CoV-2, what failed, and what those results mean for the next pandemic. For the broader fusion inhibitor strategy, see the pillar article on EK1: the pan-coronavirus fusion inhibitor peptide.
Key Takeaways
- EK1C4, a lipopeptide targeting the spike HR1 domain, inhibited SARS-CoV-2 spike-mediated fusion at 1.3 nM and pseudovirus infection at 15.8 nM, 241-fold more potent than the parent EK1 peptide (Xia et al., Cell Research, 2020).[2]
- An unmodified extended HR2 peptide achieved single-digit nanomolar inhibition of all major SARS-CoV-2 variants without chemical modification, roughly 100-fold more potent than prior short HR2 peptides (Yang et al., PNAS, 2022).[3]
- Three ACE2-mimicking stapled peptides blocked SARS-CoV-2 pseudovirus entry with IC50 values of 1.9 to 4.1 micromolar and showed zero cytotoxicity, with the lead peptide stable in human plasma for over 289 minutes (Curreli et al., mBio, 2020).[4]
- Human neutrophil peptide HNP1, enteric defensin HD5, and theta-defensin analog RC101 inhibited authentic SARS-CoV-2 and its variants by blocking viral entry, not post-entry replication (Xu et al., Viruses, 2021).[5]
- Thymosin alpha-1 reduced mortality in 76 severe COVID-19 patients from 30% to 11.1% (P=.044) by reversing T cell exhaustion and restoring lymphocyte counts (Liu et al., Clinical Infectious Diseases, 2020).[1]
- Lactoferricin blocked TMPRSS2-mediated spike priming and inhibited SARS-CoV-2 infection of permissive cells, identifying a milk-derived peptide as a TMPRSS2 inhibitor (Ohradanova-Repic et al., Frontiers in Immunology, 2022).[6]
Fusion inhibitors: the fastest response
The clearest success story came from peptides that already existed before the pandemic. EK1, a 36-amino-acid fusion inhibitor designed in 2019 to block all human coronaviruses, was immediately testable against SARS-CoV-2 because it targets the conserved HR1 domain of the spike protein rather than the mutable receptor-binding domain.[7]
By April 2020, Xia et al. had demonstrated that EK1C4, a cholesterol-conjugated lipopeptide derivative of EK1, inhibited SARS-CoV-2 spike-mediated membrane fusion with an IC50 of 1.3 nM and pseudovirus infection at 15.8 nM. This represented a 241-fold and 149-fold improvement over unmodified EK1. Intranasal application before or after SARS-CoV-2 challenge protected mice from infection.[2] A 2021 follow-up confirmed EK1C4 retained activity against Alpha, Beta, Delta, and subsequent variants of concern, with preclinical evaluation supporting development as a nasal spray.[8]
The lipid conjugation strategy was further refined when Lan et al. (2021) conjugated 25-hydroxycholesterol (25-HC) to EK1, creating EK1P4HC. The 25-HC modification exploited synergy between a known antiviral lipid and the peptide fusion inhibitor. EK1P4HC inhibited SARS-CoV-2, its variants, and common cold coronaviruses HCoV-OC43 and HCoV-229E. In a lethal challenge model, it protected newborn mice from HCoV-OC43 infection.[9]
A separate approach came from the Brunger laboratory at Stanford. Yang et al. (2022) solved the crystal structure of the SARS-CoV-2 HR1-HR2 six-helix bundle and identified an extended, well-folded N-terminal region of HR2 that previous peptide designs had missed. By designing an extended HR2 peptide incorporating this region, they achieved single-digit nanomolar inhibition of SARS-CoV-2 without any chemical modifications, roughly 100-fold more potent than all previously published short, unmodified HR2 peptides. The peptide inhibited all major variants tested and showed unusually long activity after washout, consistent with trapping a prehairpin intermediate of the spike protein.[3]
These results demonstrated that fusion inhibitor peptides can achieve potency rivaling monoclonal antibodies while maintaining activity across variants. The conserved nature of the HR1 target means resistance requires the virus to compromise its own fusion machinery.
ACE2-mimicking peptides: decoy receptors
SARS-CoV-2 enters cells by binding its receptor-binding domain (RBD) to the ACE2 receptor on human cell surfaces. A logical counterstrategy is to create peptide decoys that mimic ACE2's binding helix and intercept the virus before it reaches real receptors.
Curreli et al. (2020) designed four double-stapled peptides based on the approximately 30-amino-acid ACE2 helix that the SARS-CoV-2 RBD contacts. The chemical staples locked the peptides into alpha-helical conformations, achieving 50 to 94% helicity compared to 19% for the unstapled linear control. Three of four stapled peptides inhibited SARS-CoV-2 pseudovirus entry with IC50 values of 1.9 to 4.1 micromolar in HT1080/ACE2 cells and 2.2 to 2.8 micromolar in A549/ACE2 human lung cells.[4]
Against authentic, replication-competent SARS-CoV-2 (strain US_WA-1/2020) in Vero E6 cells, the lead peptide NYBSP-1 prevented the complete formation of cytopathic effects at 17.2 micromolar. None of the active stapled peptides showed cytotoxicity at the highest doses tested. The lead peptide NYBSP-4 had a half-life exceeding 289 minutes in human plasma, addressing a common concern about peptide degradation.[4]
The ACE2 mimetic approach has an inherent vulnerability, however. Because these peptides target the interaction between the viral RBD and ACE2, mutations in the RBD can reduce peptide binding, the same problem that afflicted monoclonal antibodies during the Omicron wave. This contrasts with HR1-targeting fusion inhibitors, where the target is structurally constrained.
Human defensins: innate immunity fights back
Defensins are small, cysteine-rich antimicrobial peptides produced by neutrophils and epithelial cells throughout the body. They are among the most abundant innate immune molecules in the human airway and gut. Their role in coronavirus defense was largely unexplored before 2020.
Xu et al. (2021) systematically tested human alpha-defensins (HNP1-4, HD5, HD6), beta-defensins (HBD2, HBD5, HBD6), and the theta-defensin analog RC101 against SARS-CoV-2. The results revealed a clear hierarchy: HNP1-3, HD5, and RC101 showed potent antiviral activity against both pseudotyped and authentic SARS-CoV-2. HNP4 and HD6 were weakly active. Beta-defensins HBD2, HBD5, and HBD6 had no detectable effect.[5]
The mechanism was entry-specific: defensins provided no protection when added after infection had begun, and HNP1 blocked viral fusion without interfering with RBD-ACE2 binding. Linear, unstructured forms of HNP1 and HD5 lost their antiviral function, confirming that the folded, disulfide-stabilized structure is essential. Pro-HD5, the unprocessed precursor of HD5, also failed to block infection.[5]
HNP1, HD5, and RC101 also blocked infection in intestinal and lung epithelial cells, the two primary sites of SARS-CoV-2 infection. The finding that high viral titers could overcome defensin protection suggests these peptides act directly on virions rather than on host cells. For more on the defensin-ACE2 interaction specifically, see how defensins may neutralize coronavirus at the ACE2 receptor.
This work raised a clinically relevant question: do patients with lower defensin levels in their airways fare worse during COVID-19? Some observational data suggests age-related declines in defensin expression correlate with COVID-19 severity, but causation remains unestablished.
Lactoferricin: a milk peptide blocks viral priming
SARS-CoV-2 requires the host protease TMPRSS2 to prime its spike protein for membrane fusion. TMPRSS2 cleaves the spike at the S2' site, exposing the fusion peptide. Blocking TMPRSS2 blocks this priming step.
Ohradanova-Repic et al. (2022) demonstrated that lactoferricin, a 25-amino-acid peptide released from lactoferrin during digestion, and a synthetic N-terminal lactoferrin peptide (pLF1) both inhibited TMPRSS2 proteolytic activity, blocked spike protein processing, and prevented SARS-CoV-2 infection of permissive cells. The finding linked lactoferricin, previously studied for antibacterial activity, to a specific mechanism against SARS-CoV-2.[6]
The TMPRSS2-targeting mechanism is distinct from both fusion inhibitors (which act later in the entry process) and ACE2-mimics (which block receptor binding). It is also less vulnerable to spike mutations because TMPRSS2 is a host protein whose expression and activity are independent of viral evolution. The limitation is that SARS-CoV-2 can also enter cells through the endosomal pathway using cathepsin L, bypassing TMPRSS2 entirely, which means TMPRSS2 inhibition alone may not achieve complete viral blockade.
Thymosin alpha-1: immunomodulation during the cytokine storm
Not all peptide strategies targeted the virus directly. Thymosin alpha-1 (Ta1), a 28-amino-acid peptide naturally produced by the thymus, was used as an immunomodulator in severe COVID-19 patients whose immune systems had collapsed into lymphocytopenia and T cell exhaustion.
Liu et al. (2020) retrospectively analyzed 76 severe COVID-19 patients at two hospitals in Wuhan during the initial outbreak (December 2019 to March 2020). Patients receiving Ta1 had a mortality rate of 11.11% compared to 30.00% in the untreated group (P=.044). Ta1 increased circulating CD4+ and CD8+ T cell counts, reduced expression of exhaustion markers PD-1 and Tim-3 on CD8+ T cells, and elevated T-cell receptor excision circles (TRECs), indicating enhanced thymic output. Patients with the most severe lymphocytopenia, those with CD8+ T cells below 400 per microliter or CD4+ T cells below 650 per microliter, gained the most benefit.[1]
This was a retrospective, non-randomized study with a small sample. Selection bias is a real concern: the treated and untreated groups may have differed in ways not captured by the analysis. Later studies produced mixed results. A 2021 study found that Ta1 did not restore CD4+ and CD8+ counts in a separate cohort of critically ill patients, though that study used different inclusion criteria and dosing protocols.
Ta1 is already an approved drug in several countries (sold as Zadaxin for hepatitis B and C), which made off-label clinical use possible during the pandemic. This regulatory head start meant it was one of the few peptide-based interventions actually administered to COVID-19 patients. For broader context on thymosin alpha-1 research, see thymosin alpha-1: the immune-modulating peptide with decades of research and thymosin alpha-1 for post-viral immune recovery.
Why no peptide was approved for COVID-19
The pandemic produced a paradox: antiviral peptides demonstrated extraordinary potency in the laboratory but none reached clinical approval. Several structural factors explain the gap.
Speed of vaccine development. mRNA vaccines reached emergency use authorization within 11 months of the viral sequence being published. This timeline exceeded even the most optimistic projections and reduced the urgency for novel therapeutics.
Small molecule competition. Paxlovid (nirmatrelvir/ritonavir), an oral protease inhibitor, received emergency authorization in December 2021. Oral bioavailability is a persistent weakness of peptide drugs, and small molecules filled the antiviral niche faster.
Delivery limitations. Most antiviral peptides work by direct contact with viral particles or host cell surfaces. Systemic delivery requires overcoming rapid proteolytic degradation and poor membrane permeability. Intranasal delivery, which EK1C4 used successfully in mice, is promising but requires formulation development and clinical trials that take years.
Regulatory pathways. No peptide antiviral had ever been approved for a respiratory virus. Enfuvirtide (HIV fusion inhibitor, approved 2003) and bulevirtide (hepatitis B/D entry inhibitor, approved 2020) established that peptide antivirals can reach the market, but for viruses with very different clinical contexts. Building a regulatory pathway for a peptide nasal spray against respiratory viruses during an emergency is not straightforward.
Funding allocation. Government and industry funding overwhelmingly prioritized vaccines and repurposed drugs. Peptide antiviral programs received a fraction of the resources directed at mRNA vaccines or monoclonal antibody production.
These barriers are not permanent. Intranasal delivery systems are advancing. Manufacturing costs for synthetic peptides have decreased. And the next pandemic will not arrive with the same specific characteristics as COVID-19, meaning vaccines may not be developable as quickly.
What the pandemic taught peptide science
The SARS-CoV-2 experience produced several lessons that reshape antiviral peptide strategy going forward.
Pre-positioned broad-spectrum peptides have value. EK1 existed before the pandemic and was testable within weeks of the sequence release. Peptides designed against conserved viral features, not just the pathogen of the moment, have strategic value for pandemic preparedness.
Multiple mechanisms can be combined. The pandemic revealed at least nine distinct peptide strategies: fusion inhibitors, ACE2 decoys, TMPRSS2 blockers, defensins, Mpro-targeting cyclic peptides, immunomodulators (thymosin alpha-1), lactoferrin-derived peptides, LL-37/cathelicidin, and peptide vaccines. Combination approaches that target multiple steps of viral entry could provide more robust protection than any single peptide. EK1P4HC demonstrated this by combining a fusion inhibitor peptide with an antiviral lipid for synergistic activity.[9]
Targeting host factors reduces resistance risk. Peptides targeting TMPRSS2 (lactoferricin) or mimicking host receptors (ACE2 stapled peptides) face less resistance pressure than those targeting mutable viral epitopes. This advantage grows as viruses accumulate spike mutations.
In vitro potency does not guarantee clinical utility. Nanomolar IC50 values in cell culture do not automatically translate to therapeutic efficacy. The gap between cell-based assays and protection in living organisms requires pharmacokinetic optimization, formulation science, and clinical trials that the pandemic's compressed timeline could not accommodate.
Innate immune peptides deserve investment. The defensin findings suggest that the body's existing peptide armory plays a role in coronavirus defense. Understanding why some individuals produce more defensins than others, and whether this correlates with clinical outcomes, could reveal new therapeutic targets. The link between vitamin D and LL-37 production adds another dimension, as vitamin D deficiency has been independently associated with worse COVID-19 outcomes.
The Bottom Line
The SARS-CoV-2 pandemic demonstrated that antiviral peptides can achieve nanomolar potency against a novel coronavirus through at least nine distinct mechanisms, from fusion inhibition to immune restoration. No peptide reached clinical approval for COVID-19, blocked by delivery challenges, small molecule competition, and the unprecedented speed of mRNA vaccine development. The primary legacy is strategic: pre-designed broad-spectrum peptides like EK1 and its derivatives, targeting conserved viral machinery rather than mutable surface epitopes, represent a platform for pandemic preparedness that now has extensive preclinical validation.